U.S. Markets closed
  • S&P 500

    4,158.24
    +100.40 (+2.47%)
     
  • Dow 30

    33,212.96
    +575.77 (+1.76%)
     
  • Nasdaq

    12,131.13
    +390.48 (+3.33%)
     
  • Russell 2000

    1,887.90
    +49.66 (+2.70%)
     
  • Crude Oil

    115.07
    +0.98 (+0.86%)
     
  • Gold

    1,857.30
    +3.40 (+0.18%)
     
  • Silver

    22.14
    +0.17 (+0.77%)
     
  • EUR/USD

    1.0739
    +0.0006 (+0.0537%)
     
  • 10-Yr Bond

    2.7430
    -0.0130 (-0.47%)
     
  • Vix

    25.72
    -1.78 (-6.47%)
     
  • GBP/USD

    1.2631
    +0.0025 (+0.2021%)
     
  • USD/JPY

    127.0850
    -0.0170 (-0.0134%)
     
  • BTC-USD

    28,994.62
    +139.42 (+0.48%)
     
  • CMC Crypto 200

    625.79
    -3.71 (-0.59%)
     
  • FTSE 100

    7,585.46
    +20.54 (+0.27%)
     
  • Nikkei 225

    26,781.68
    +176.84 (+0.66%)
     

Surface Oncology Rises on Rumor ARK's Cathie Wood Will Talk About It At Event

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

By Dhirendra Tripathi

Investing.com – Surface Oncology (NASDAQ:SURF) shares rose 2.6% in Wednesday’s trade on market chatter that ARK founder and fund manager Cathie Wood will talk about the company at an event today.

ARK Genomic Revolution ETF (NYSE:ARKG), which is managed by Wood, has around a 0.4% stake in the company, according to Seeking Alpha.

Seeking Alpha says funds managed by Ark Investment have sharply raised their holdings in Surface Oncology over last few months.

Surface has successfully built its business model around partnerships with the likes of GlaxoSmithKline (NYSE:GSK) and Novartis (NYSE:NVS) to develop innovative cancer immunotherapies.

For the full year ended December 31, Surface reported a net income of $59.3 million against a net loss of $54.8 million for the same period in 2019.

Revenue of $126.2 million, compared to $15.4 million for the same period in 2019, got a boost from GSK’s $85 million upfront payment.

Related Articles

Disney Reverses Losses As CEO Says California Park to Reopen

Airline consolidation set back five years, IATA chief says

Benefits outweigh the risks of AstraZeneca COVID shot as review continues: WHO